Narsoplimab
([OMS721],MASP-2 inhibitor,lectin pathway)
Stem Cell Transplant-Associated TMA (TA-TMA)
COVID-19 and ARDS
Our Pipeline
We think differently and innovate relentlessly in pursuit of elegant solutions to the most difficult challenges facing patients. Our next-generation therapeutics are transforming patient care today.
Our cutting-edge science serves as the foundation for a deep and diverse pipeline of small-molecule and protein therapeutics focused on significant unmet medical needs – a pipeline of first-in-class drugs with new mechanisms of action that target previously untapped receptors and enzymes.
Omeros has retained exclusive control of worldwide commercial rights for all products, product candidates, and programs (except zaltenibart).
([OMS721],MASP-2 inhibitor,lectin pathway)
Stem Cell Transplant-Associated TMA (TA-TMA)
COVID-19 and ARDS
([OMS906],MASP-3 inhibitor,alternative pathway)

Novo Nordisk is developing zaltenibart under an asset acquisition and licensing agreement in PNH. Novo Nordisk is also pursuing zaltenibart in other rare hematologic and renal disorders.
(MASP-2 inhibitor)
Long-Acting 2nd Generation Antibody Targeting Lectin Pathway Disorders
Disorders of the Lectin and Alternative Pathways of Complement
(PDE7 inhibitor)
Addictions and Compulsive Disorders; Movement Disorders
Cancer
Cancer
Immunologic, CNS, Metabolic, CV, Musculoskeletal & Other Disorders